Genzyme Biosurgery Restructuring Emphasizes R&D Over Hardware
This article was originally published in The Gray Sheet
Executive Summary
Genzyme Biosurgery intends to redirect a portion of its roughly $45 mil. annual R&D budget toward early stage studies of cell therapy for cardiac indications and potential uses of gene therapy during cardiac surgery.